BR0003282A - Pharmaceutical association for the treatment of arterial hypertension and the prevention of other cardiovascular diseases, such as myocardial infarction, stroke and heart and kidney failure - Google Patents
Pharmaceutical association for the treatment of arterial hypertension and the prevention of other cardiovascular diseases, such as myocardial infarction, stroke and heart and kidney failureInfo
- Publication number
- BR0003282A BR0003282A BR0003282-4A BR0003282A BR0003282A BR 0003282 A BR0003282 A BR 0003282A BR 0003282 A BR0003282 A BR 0003282A BR 0003282 A BR0003282 A BR 0003282A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- myocardial infarction
- cardiovascular diseases
- kidney failure
- heart
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"ASSOCIAçãO FARMACêUTICA PARA TRATAMENTO DE HIPERTENSãO ARTERIAL E PREVENçãO DE DOENçAS CARDIOVASCULARES OUTRAS, COMO INFARTO DO MIOCáRDIO, ACIDENTE VASCULAR CEREBRAL E INSUFICIêNCIAS CARDìACA E RENAL". A presente invenção se refere à associação, numa mesma unidade farmacotécnica, cápsula e comprimido, mantendo-se os dois fármacos isolados fisicamente, da Amlodipina, um antagonista de cálcio, com o Ramipril, um inibidor da enzima conversora de angiotensina, ou seus respectivos sais, que é útil no tratamento da hipertensão arterial, prevenindo doenças cardiovasculares outras, como infarto do miocárdio, acidente vascular cerebral e insuficiências cardíaca e renal."PHARMACEUTICAL ASSOCIATION FOR TREATMENT OF ARTERIAL HYPERTENSION AND PREVENTION OF OTHER CARDIOVASCULAR DISEASES, LIKE MYOCARDIAL INFARCTION, CEREBRAL VASCULAR ACCIDENT AND KIDNEY FAILURE". The present invention relates to the association, in the same pharmacotechnical unit, of capsule and tablet, keeping the two drugs physically isolated, from Amlodipine, a calcium antagonist, with Ramipril, an inhibitor of the angiotensin-converting enzyme, or their respective salts , which is useful in the treatment of high blood pressure, preventing other cardiovascular diseases, such as myocardial infarction, stroke and heart and kidney failure.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0003282-4A BR0003282A (en) | 2000-07-14 | 2000-07-14 | Pharmaceutical association for the treatment of arterial hypertension and the prevention of other cardiovascular diseases, such as myocardial infarction, stroke and heart and kidney failure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0003282-4A BR0003282A (en) | 2000-07-14 | 2000-07-14 | Pharmaceutical association for the treatment of arterial hypertension and the prevention of other cardiovascular diseases, such as myocardial infarction, stroke and heart and kidney failure |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0003282A true BR0003282A (en) | 2002-02-26 |
Family
ID=3944810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0003282-4A BR0003282A (en) | 2000-07-14 | 2000-07-14 | Pharmaceutical association for the treatment of arterial hypertension and the prevention of other cardiovascular diseases, such as myocardial infarction, stroke and heart and kidney failure |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR0003282A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014076632A1 (en) | 2012-11-15 | 2014-05-22 | Adamed Sp. Z O.O. | A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker |
-
2000
- 2000-07-14 BR BR0003282-4A patent/BR0003282A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014076632A1 (en) | 2012-11-15 | 2014-05-22 | Adamed Sp. Z O.O. | A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Camm et al. | Edoxaban: a new oral direct factor xa inhibitor | |
Baxter et al. | Stockley's drug interactions | |
Gradman | Rationale for triple‐combination therapy for management of high blood pressure | |
AU635881B2 (en) | Oral anticoagulant/platelet inhibitor low dose formulation | |
Sood et al. | Combination therapy for the management of hypertension: a review of the evidence | |
US20070009614A1 (en) | Composition and method for treating hypertension | |
BR0116228A (en) | Therapeutic combination of amlodipine and benazepril / benazeprilat | |
BG66115B1 (en) | USE OF RAMIPRIL OR ITS PHARMACEUTICAL ACCEPTABLE SALT FOR PREVENTION OF CONGRESSIVE CARDIAC INCORRECT | |
HUP0104249A2 (en) | Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease | |
Gorostidi et al. | Combination therapy in hypertension | |
MA30779B1 (en) | PEDIATRIC TABLETS OF CAPECITABINE | |
PL404315A1 (en) | A drug and pharmaceutical composition comprising 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine for the treatment of severe heart failure and use thereof for the manufacture of a medicament | |
BR0003282A (en) | Pharmaceutical association for the treatment of arterial hypertension and the prevention of other cardiovascular diseases, such as myocardial infarction, stroke and heart and kidney failure | |
Kjeldsen et al. | Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension | |
MacWalter et al. | A benefit-risk assessment of agents used in the secondary prevention of stroke | |
Oparil et al. | Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy | |
Krzesinski et al. | ExforgeŴ (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact | |
BR9905016A (en) | Pharmaceutical preparation for arterial hypertension | |
KR20180041233A (en) | A pharmaceutical composition comprising an HMG-CoA reductase inhibitor and an ECA inhibitor | |
Kelly et al. | Efficacy and Safety of a polypill to reduce cardiovascular events: A review of clinical trials. | |
MacIntrye et al. | Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure | |
Garavaglia et al. | Angiotensin converting enzyme inhibitors: disparities in the mechanism of their antihypertensive effect | |
Sanghavi et al. | Amlodipine Induced Severe Pedal Edema: A Case Report from a Tertiary Care Hospital | |
SAMA/Acute Coronary Syndrome Working Group | Management of acute coronary syndromes clinical guideline | |
Scoble | Renal artery stenosis as a cause of renal impairment: implications for treatment of hypertension and congestive heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
B09B | Decision: refusal |
Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 13, 24 E 25 DA LPI. |
|
B09B | Decision: refusal |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |